Every 10-Q that Champions Oncology, Inc. (CSBR) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow CSBR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CSBR filings page.
Champions Oncology, Inc. (CSBR) reported higher revenue but continued modest losses for the quarter ended July 31, 2026. Oncology revenue rose to $15.2 million from $14.0 million a year earlier, an 8.8% increase, driven mainly by pharmacology services and strong growth in data license revenue.
Net loss was $426,000 (basic loss per share $0.03), slightly improved from a $466,000 loss in the prior-year quarter as gross margin expanded; cost of oncology revenue fell 5.8% to $7.5 million. Operating cash flow was a use of $492,000 versus $600,000 provided a year ago, reflecting working-capital movements and higher operating spending.
Cash stood at $4.4 million with working capital of $563,000. Management states that existing cash and expected operating cash flows are adequate to fund operations through at least September 2027. Total assets increased to $33.3 million, mainly due to a long-term Rockville facility lease amendment that lifted operating right-of-use assets and lease liabilities. Internal controls over financial reporting are described as effective, and no material legal proceedings are disclosed.
Champions Oncology reported slightly lower quarterly oncology revenue of $16.6M, down from $17.0M a year ago, and swung to a net loss of $0.3M compared with prior net income of $4.5M. Higher outsourced lab work, especially radiolabeling, plus increased research, sales, and administrative spending drove costs up faster than revenue.
For the nine months ended January 31, 2026, revenue rose modestly to $45.6M from $44.6M, but results moved from net income of $6.5M to a net loss of $0.5M. The company used $2.5M of cash in operations and ended the period with $7.1M in cash, negative working capital of about $0.5M, and an accumulated deficit of roughly $80.4M. Management nevertheless believes existing cash and expected operating cash flows can fund operations through at least March 2027.
Champions Oncology reported higher revenue but weaker profitability for the quarter ended October 31, 2025. Oncology revenue grew to $15,035,000 from $13,489,000, an 11.5% increase, driven mainly by pharmacology services, which rose to $14,515,000 from $12,498,000. TOS data license revenue contributed $157,000 versus none a year ago, while other TOS revenue declined to $363,000 from $991,000 as flow cytometry and SaaS activity fell.
Income from operations for the quarter declined to $185,000 from $732,000, and net income attributable to common shares was $268,000 versus $728,000, or $0.02 per diluted share compared with $0.05. For the six months, oncology revenue increased to $29,030,000, but results swung to a loss from operations of $342,000 and a net loss attributable to common shares of $169,000, compared with income of $2,061,000 and $2,041,000, respectively, a year earlier. Higher research and development, sales and marketing, and general and administrative expenses reflect investment in the company’s data licensing platform and its Corellia target-discovery subsidiary. Cash was $8,516,000 with negative operating cash flow of $1,135,000, yet management believes existing cash and expected cash flows can fund operations through at least December 2026.